With Sarepta funding Fletcher and Wilton's research and with Sarepta expecting US$225mill from their current cr (see link below), this work is looking more and more like a licensing opportunity for PYC.
Concerning Sarepta's cr, I pulled this from the following article:
The capital raised will be used for funding ongoing and future clinical trials, commercialization and marketing activities, production and any opportunities for licensing or acquiring suitable products or technologies.
http://www.investopedia.com/news/sarepta-announces-offering-common-stock-srpt/
SoT
DYOR
Ann: Cell-Penetrating Phylomers Improve Delivery of Drugs-PYC.AX, page-83
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.27 |
Change
0.005(0.40%) |
Mkt cap ! $740.7M | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.29 | $1.27 | $406.0K | 319.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13987 | $1.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 1380 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |